Literature DB >> 8419938

Soluble CD4 enhances the efficacy of immunotoxins directed against gp41 of the human immunodeficiency virus.

S H Pincus1, J McClure.   

Abstract

Monoclonal antibodies specific for the gp120 or gp41 portions of the human immunodeficiency virus (HIV) envelope protein gp160 were conjugated to ricin A chain, and their immunotoxic activities against HIV-infected cells were evaluated in the presence or absence of soluble CD4 (sCD4). Immunotoxin activity was measured in vitro as cytotoxicity and inhibition of secretion of infectious HIV. The efficacy of anti-gp41 immunotoxins was enhanced at least 30-fold in the presence of sCD4. This effect was specific for HIV-infected cells, but not for uninfected cells, and was seen at concentrations of sCD4 as low as 0.1 micrograms/ml. Anti-gp120 immunotoxins were marginally inhibited at higher concentrations of sCD4. Flow cytometry analyses showed that sCD4 increased the expression of gp41 on the surface of infected cells and increased internalization of gp120 and gp41. These data suggest that sCD4 alters the cellular trafficking of HIV envelope proteins. These findings also have important implications for the therapeutic use of anti-HIV immunotoxins and may be generalizable to other immunotoxins as well.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8419938      PMCID: PMC45654          DOI: 10.1073/pnas.90.1.332

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  27 in total

1.  The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain.

Authors:  P J Maddon; A G Dalgleish; J S McDougal; P R Clapham; R A Weiss; R Axel
Journal:  Cell       Date:  1986-11-07       Impact factor: 41.582

2.  Designing CD4 immunoadhesins for AIDS therapy.

Authors:  D J Capon; S M Chamow; J Mordenti; S A Marsters; T Gregory; H Mitsuya; R A Byrn; C Lucas; F M Wurm; J E Groopman
Journal:  Nature       Date:  1989-02-09       Impact factor: 49.962

3.  In vivo administration of lymphocyte-specific monoclonal antibodies in nonhuman primates. In vivo stability of disulfide-linked immunotoxin conjugates.

Authors:  N L Letvin; V S Goldmacher; J Ritz; J M Yetz; S F Schlossman; J M Lambert
Journal:  J Clin Invest       Date:  1986-03       Impact factor: 14.808

4.  Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone.

Authors:  A Adachi; H E Gendelman; S Koenig; T Folks; R Willey; A Rabson; M A Martin
Journal:  J Virol       Date:  1986-08       Impact factor: 5.103

5.  A soluble recombinant polypeptide comprising the amino-terminal half of the extracellular region of the CD4 molecule contains an active binding site for human immunodeficiency virus.

Authors:  E A Berger; T R Fuerst; B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1988-04       Impact factor: 11.205

6.  In vivo administration of lymphocyte-specific monoclonal antibodies in nonhuman primates. Delivery of ribosome-inactivating proteins to spleen and lymph node T cells.

Authors:  N L Letvin; L V Chalifoux; K A Reimann; J Ritz; S F Schlossman; J M Lambert
Journal:  J Clin Invest       Date:  1986-09       Impact factor: 14.808

Review 7.  Redesigning nature's poisons to create anti-tumor reagents.

Authors:  E S Vitetta; R J Fulton; R D May; M Till; J W Uhr
Journal:  Science       Date:  1987-11-20       Impact factor: 47.728

8.  Monoclonal anti-(T,G)-A--L antibodies: characterization of fine specificity and idiotype expression.

Authors:  S H Pincus; C J Stocks; L P Ewing
Journal:  Mol Immunol       Date:  1982-12       Impact factor: 4.407

9.  Selective killing of HIV-infected cells by recombinant human CD4-Pseudomonas exotoxin hybrid protein.

Authors:  V K Chaudhary; T Mizukami; T R Fuerst; D J FitzGerald; B Moss; I Pastan; E A Berger
Journal:  Nature       Date:  1988-09-22       Impact factor: 49.962

10.  HIV-infected cells are killed by rCD4-ricin A chain.

Authors:  M A Till; V Ghetie; T Gregory; E J Patzer; J P Porter; J W Uhr; D J Capon; E S Vitetta
Journal:  Science       Date:  1988-11-25       Impact factor: 47.728

View more
  11 in total

1.  Identification of Human Anti-HIV gp160 Monoclonal Antibodies That Make Effective Immunotoxins.

Authors:  Seth H Pincus; Kejing Song; Grace A Maresh; Dean H Hamer; Dimiter S Dimitrov; Weizao Chen; Mei-Yun Zhang; Victor F Ghetie; Po-Ying Chan-Hui; James E Robinson; Ellen S Vitetta
Journal:  J Virol       Date:  2017-01-18       Impact factor: 5.103

2.  Design and In Vivo Characterization of Immunoconjugates Targeting HIV gp160.

Authors:  Seth H Pincus; Kejing Song; Grace A Maresh; Anderson Frank; David Worthylake; Hye-Kyung Chung; Patricia Polacino; Dean H Hamer; Cody P Coyne; Michael G Rosenblum; John W Marks; Gang Chen; Deborah Weiss; Victor Ghetie; Ellen S Vitetta; James E Robinson; Shiu-Lok Hu
Journal:  J Virol       Date:  2017-01-18       Impact factor: 5.103

3.  Processing of the envelope glycoprotein gp160 in immunotoxin-resistant cell lines chronically infected with human immunodeficiency virus type 1.

Authors:  T D Duensing; H Fang; D W Dorward; S H Pincus
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

4.  Unique insertion sequence and pattern of CD4 expression in variants selected with immunotoxins from human immunodeficiency virus type 1-infected T cells.

Authors:  H Fang; S H Pincus
Journal:  J Virol       Date:  1995-01       Impact factor: 5.103

5.  Anti-HIV double variable domain immunoglobulins binding both gp41 and gp120 for targeted delivery of immunoconjugates.

Authors:  Ryan B Craig; Christopher M Summa; Miriam Corti; Seth H Pincus
Journal:  PLoS One       Date:  2012-10-04       Impact factor: 3.240

6.  Targeted cytotoxic therapy kills persisting HIV infected cells during ART.

Authors:  Paul W Denton; Julie M Long; Stephen W Wietgrefe; Craig Sykes; Rae Ann Spagnuolo; Olivia D Snyder; Katherine Perkey; Nancie M Archin; Shailesh K Choudhary; Kuo Yang; Michael G Hudgens; Ira Pastan; Ashley T Haase; Angela D Kashuba; Edward A Berger; David M Margolis; J Victor Garcia
Journal:  PLoS Pathog       Date:  2014-01-09       Impact factor: 6.823

Review 7.  Increasing the Clinical Potential and Applications of Anti-HIV Antibodies.

Authors:  Casey K Hua; Margaret E Ackerman
Journal:  Front Immunol       Date:  2017-11-28       Impact factor: 7.561

8.  Selective cytotoxicity of a novel immunotoxin based on pulchellin A chain for cells expressing HIV envelope.

Authors:  Mohammad Sadraeian; Francisco E G Guimarães; Ana P U Araújo; David K Worthylake; Louis Jr LeCour; Seth H Pincus
Journal:  Sci Rep       Date:  2017-08-08       Impact factor: 4.379

9.  Photoimmunotherapy Using Cationic and Anionic Photosensitizer-Antibody Conjugates against HIV Env-Expressing Cells.

Authors:  Mohammad Sadraeian; Calise Bahou; Edgar Ferreira da Cruz; Luíz Mário Ramos Janini; Ricardo Sobhie Diaz; Ross W Boyle; Vijay Chudasama; Francisco Eduardo Gontijo Guimarães
Journal:  Int J Mol Sci       Date:  2020-12-01       Impact factor: 5.923

Review 10.  Antibody Conjugates for Targeted Therapy Against HIV-1 as an Emerging Tool for HIV-1 Cure.

Authors:  Jeffrey C Umotoy; Steven W de Taeye
Journal:  Front Immunol       Date:  2021-07-01       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.